Startup profile · funding coverage
Elegen
Next-generation cell-free DNA synthesis for genetic medicine and vaccine manufacturing.
Stage
series b
Status
private
Coverage
full
Why Elegen is interesting
Elegen speeds GMP-compliant DNA production for genetic medicine — 8VC joined a16z in its $35M Series B in 2024.
Key facts
- Series B (May 2024): $35M led by Triatomic Capital; 8VC and a16z Bio + Health re-upped (Businesswire)
- Source: https://elegenbio.com/news/elegen-raises-35-million-in-series-b-to-accelerate-expansion-into-clinical-manufacturing/
Investors in our directory
Funds linked from Elegen's profile — open a fund page for stage focus and related deal articles.
Industries
Biotech & Life Sciences
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
FAQs about Elegen
Funding context and why this company shows up in venture coverage.
Elegen produces high-quality synthetic DNA using a cell-free manufacturing process — supplying genetic medicine developers with faster, GMP-ready DNA for research and clinical manufacturing.
Andreessen Horowitz (/fund/andreessen-horowitz) and 8VC (/fund/8vc) participated in the $35M Series B in May 2024 led by Triatomic Capital.
Elegen raised a $35M Series B in May 2024 to expand into clinical manufacturing. It remains a private biotech.
DNA synthesis is a bottleneck for mRNA, gene therapy, and CRISPR programs — Elegen's cell-free platform targets faster turnaround for GMP-grade genetic material.
No. Elegen is privately held as of July 2026.
Last updated: 2026-07-24